Do the potential benefits outweigh the risks? An update on the use of ziconotide in clinical practice

@article{Bckryd2018DoTP,
  title={Do the potential benefits outweigh the risks? An update on the use of ziconotide in clinical practice},
  author={E. B{\"a}ckryd},
  journal={European Journal of Pain},
  year={2018},
  volume={22}
}
  • E. Bäckryd
  • Published 2018
  • Medicine
  • European Journal of Pain
  • Ziconotide is a selective and potent blocker of N‐type voltage‐gated calcium channels. It was approved by the Food and Drug Administration in 2004 and by the European Medicines Agency in 2005 for the treatment of severe chronic pain in patients needing intrathecal analgesia (ITA). The aim of this paper is to provide a practitioner‐oriented, educational, narrative, up‐to‐date review on the use of ziconotide in clinical pain medicine. Of special concern regarding safety is the partial incongruity… CONTINUE READING

    Topics from this paper.

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 103 REFERENCES
    Ziconotide for treatment of severe chronic pain
    • 231
    • Highly Influential
    • PDF
    Ziconotide: neuronal calcium channel blocker for treating severe chronic pain.
    • 420
    Ziconotide: a clinical update and pharmacologic review
    • 86
    A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain.
    • 231
    • Highly Influential
    Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain
    • 65
    • Highly Influential
    • PDF